Company intelligence / Profile preview

UniTargetingResearch

Ownership: Private
Development stage: Commercial

Overview

The company has developed and commercialized the ColoAlert test for colorectal cancer detection, which has been sold to Mainz Biomed NV but UTR remains involved in its further development. The test is currently available in Europe and other international markets.

Therapeutic areas: Oncology
Modalities: Nucleic acid-based diagnosticsGenetic engineering tools
Industry: Molecular Diagnostics

Partnerships

Mainz Biomed NVGlobal biopharmaceutical companiesClinical laboratories in Europe

Beyond the preview

Go deeper on UniTargetingResearch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UniTargetingResearch.

Explore the full profile